NAFLD/NASH: a novel pro-carcinogenic contribution for oncostatin M

Oncostatin M is a pleiotropic cytokine of the interleukin (IL)-6 family that contributes to the progression of chronic liver disease. G. Di Maira et al. (University of Firenze, Italy) aimed to investigate the role of oncostatin M in the development and progression of hepatocellular.....
PUBLISHED IN: J Pathol 2022

Commentary

Oncostatin M is a pleiotropic cytokine of the interleukin (IL)-6 family that contributes to the progression of chronic liver disease.

G. Di Maira et al. (University of Firenze, Italy) aimed to investigate the role of oncostatin M in the development and progression of hepatocellular carcinoma in NAFLD/NASH.

In a murine model of NAFLD/NASH-related hepatocarcinogenesis, and in analysis of liver specimens from human NASH-related HCCs with vascular invasion, oncostatin M up-regulation appears to be a specific feature of HCC arising on a NAFLD/NASH background, and it correlates with clinical parameters and disease outcome. For the authors, these data highlight a novel pro-carcinogenic contribution for oncostatin M in NAFLD/NASH.

Share the article
Avatar photo

Dr. D. Beard

DR. D. BEARD is specialist of Nash Pathology

Articles: 191

Leave a Reply

Your email address will not be published. Required fields are marked *

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES